Invigor kicks off China Insights trial for self-service convenience stores

|

Published 11-DEC-2018 11:43 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Invigor Group’s (ASX:IVO) Shopper Insights solution will soon be trialled in Guangzhou, China at EasyGo convenience stores — self-serve, staff-less stores that use WeChat Pay, similar to Amazon Go in North America.

Further to that, IVO has confirmed that during the past eight months, two groups in Australia — a national retailer and a major shopping centre group, both of which are household names — have successfully completed trials of Shopper Insights prior to revenue-generating deployments.

IVO itself is a B2B data intelligence and solutions company that turns data analytics into dollars for the retail and service industries. Its innovation in owned retail platforms and unique cross-channel data ecosystem gives businesses a holistic view of their customers and competitive landscape, enabling them to not only understand but also effectively engage with consumers.

Playing a central role in this is Shopper Insights, which provides unprecedented data on consumers and their habits, giving retailers and brands deep insights into their most valued customers, driving more personalised forms of engagement. This enables them to better influence and reward shoppers, thus increasing long-term loyalty.

Leveraging advanced machine learning algorithms, Shopper Insights also assesses the impact of marketing, merchandising, merchant acquisition and promotional initiatives, making recommendations on how these can be improved and enhanced.

Invigor CEO, Gary Cohen, said: “Our partnership with Winning Group and WeChat Pay continues to strengthen and this trial in Guangzhou gives us a toehold into China, which could have huge potential. This is a major opportunity in a large population centre and extends our partnership into one of the world’s largest retail markets.

“Shopper Insights is a key component of the Loyalty solution that we will roll out through the WeChat pay opportunities that we are pursuing in Hong Kong, Singapore and Japan.

“Closer to home, the trials just completed with two very recognised household names present us with further growth opportunities in the Australian market for this solution, which has significant untapped potential for this type of technology.”

Cohen added that further updates on IVO's progress in Australia and Asia are pending as the company locks in more annualised recurring revenue streams from its core operations.

This latest development follows on from the expansion of IVO’s collaboration with Winning Group last month, which sees IVO integrating its Loyalty solution in the WeChat platform for South-East Asian and Japanese markets.

The small cap also recently extended its partnership with Microsoft. This gives IVO a global sales platform and network for which to promote and sell its Loyalty and Pricing solutions.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X